Proneurotensin/neuromedin N secreted from small cell lung carcinoma cell lines as a potential tumor marker

Proteomics - Clinical Applications

Volumn 2, Issue 12, 2008, Pages 1620-1627

  Ogura, Shun Ichiro ^a   Kaneko, Kumi ^a   Miyajima, Shoji ^a   Ohshima, Keiichi ^a   Yamaguchi, Ken ^a   Mochizuki, Tohru ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Neuromedin N; Proneurotensin; Serum free conditioned medium; Small cell lung cararcinoma; Tandem mass spectrometry; Tumormarker

Indexed keywords

BETA ACTIN; CHAPERONIN; CYCLOPHILIN A; HEAT SHOCK PROTEIN 90; MIGRATION INHIBITION FACTOR; NEUROMEDIN N; NEUROTENSIN; ONCOPROTEIN; PRONEUROTENSIN; TUMOR MARKER; UBIQUITIN; UNCLASSIFIED DRUG; VIMENTIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 58449092046     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800039     Document Type: Article

References (29)

1. Stieber, P., Dienemann, H., Schalhon, A., Schmitt, U. M. et al., Progastrin-releasing peptide (ProGRP) - A useful marker in small cell lung carcinomas. Anticancer Res. 1999, 19, 2673-2678.
2. Miyake, Y., Kodama, T., Yamaguchi, K., Progastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res. 1994, 54, 2136-2140.
3. Honda, K., Hayashida, Y., Umaki, T., Okusaka, T. et al., Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 2005, 65, 10613-10622.
4. Bhanot, G., Alexe, G., Venkataraghavan, B., Levine, J. A., A robust meta-classification strategy for cancer detection from MS data. Proteomics 2006, 6, 592-604.
5. Yanagisawa, K., Shyr, Y., Xu, J. B., Massion, P. P. et al., Proteomic patterns of tumour subsets in nonsmall-cell lung cancer. Lancet 2003, 362, 433-439.
6. Lam, Y. W., Mobley, J. A., Evans, J. E., Carmody, J. F., Ho, S.-M., Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 2005, 5, 2927-2938.
7. Pardo, M., Garcia, A., Thomas, B., Pinerio, A. et al., Proteome analysis of a human uveal melanoma primary cell culture by 2-DE and MS. Proteomics 2005, 5, 4980-4993.
8. Xiang, R., Shi, Y., Dillon, D. A., Negin, B. et al., 2D LC/MS analysis of membrane proteins from breast cancer cell lines MCF7 and BT474. J. Proteome Res. 2004, 3, 1278-1283.
9. Howard, B. A., Zheng, Z., Campa, M. J., Wang, M. Z. et al., Translating biomarkers into clinical practice: Prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004, 46, 313-323.
10. Campa, M. J., Wang, M. Z., Howard, B., Fitzgerald, M. C., Patz, E. F., Jr., Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in nonsmall cell lung cancer. Cancer Res. 2003, 63, 1652-1656.
11. Guo, J., Yang, E. C., Desouza, L., Diehl, G. et al., A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: Calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma. Proteomics 2005, 5, 1953-1966.
12. DeSouza, L., Diehl, G., Rodrigues,M. J., Guo, J. et al., Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 2005, 4, 377-386.
13. Hamler, R. L., Zhu, K., Buchanan, N. S., Kreunin, P. et al., A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics 2004, 4, 562-577.
14. Wang, H., Kachman, M. T., Schwartz, D. R., Cho, K. R., Lubman, D. M., Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: A strategy for identification of candidate cancer biomarkers. Proteomics 2004, 4, 2476-2495.
15. Sasaki, K., Sato, K., Akiyama, Y., Yanamihara, K. et al., Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Res. 2002, 62, 4894-4898.
16. Sato, K., Sasaki, K., Akiyama, Y., Yamaguchi, K., Mass spectrometric high-throughput analysis of serum-free conditioned medium from cancer cell lines. Cancer Lett. 2001, 170, 153-159.
17. Davis, T. P., Crowell, S., McInturff, B., Louis, R., Gillespic, T., Neurotensin may function as a regulatory peptide in small cell lung cancer. Peptides 1991, 12, 17-23.
18. Cuttitta, F., Carney, D. N., Mulshine, J., Moody, T. W. et al., Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985, 316, 823-826.
19. Moody, T. W., Pert, C. B., Gazdar, A. F., Carney, D. N., Minna, J. D., High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science 1981, 214, 1246-1248.
20. Pendersen, J. H., Fahrenkrug, J., Neurotensin-like immunoreactivities in human plasma: Feeding responses and metabolism. Peptides 1986, 7, 15-20.
21. Kislauskis, E., Bullock, B., McNeil, S., Dobner, P. R., The rat gene encoding neurotensin and neuromedin N. Structure, tissue-specific expression, and evolution of exon sequences. J. Biol. Chem. 1988, 263, 4963-4968.
22. Camby, I., Salmon, I., Bourded, E., Nagy, N. et al., Neurotensin-mediated effects on astrocytic tumor cell proliferation. Neuropeptides 1996, 30, 133-139.
23. Iwase, K., Evers, B. M., Hellmich, M. R., Kim, H. J. et al., Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer 1997, 79, 1787-1793.
24. Seethalakshmi, L., Mitra, S. P., Dobner, P. R., Menon, M., Carraway, R. E., Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997, 31, 183-192.
25. Bozou, J. C., Amar, S., Vincent, J. P., Kitabgi, P., Neurotensin-mediated inhibition of cyclic AMP formation in neuroblastoma N1E115 cells: Involvement of the inhibitory GTP-binding component of adenylate cyclase. Mol. Pharmacol. 1986, 29, 489-496.
26. Reubi, J. C., Waser, B., Schaer, J.-C., Laissue, J. A., Neurotensin receptors in human neoplasms: High incidence in Ewing's sarcomas. Int. J. Cancer 1999, 82, 213-218.
27. Barelli, H., Fox-Threlkeld, J. E., Dive, V., Daniel, E. E. et al., Role of endopeptidase 3.4.24.16 in the catabolism of neurotensin, in vivo, in the vascularly perfused dog ileum. Br. J. Pharmacol. 1994, 112, 127-132.
28. Checler, F., Vincent, J. P., Kitabgi, P., Neuromedin N: High affinity interaction with brain neurotensin receptors and rapid inactivation by brain synaptic peptidases. Eur. J. Pharmacol. 1986, 126, 239-244.
29. Friry, C., Feliciangeli, S., Richard, F., Kitabgi, P., Rovere, C., Production of recombinant large proneurotensin/neuromedin N-derived peptides and characterization of their binding and biological activity. Biochem. Biophys. Res. Commun. 2002, 290, 1161-1168.